AKT1 and neoplasm: This study provides comprehensive evidence supporting the efficacy of CUDC-907 in EC, demonstrating its ability to inhibit tumor growth, restore PR expression, suppress the PI3K/Akt pathway, and reduce serum IGF-1 levels, particularly in obesity-driven disease models.